CoChat
Sign Up
Cited by 425

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Pancreatic cancer-targeting exosomes for enhancing immunotherapy and reprogramming tumor microenvironment

Zhou, Wenxi, Zhou, Yu, Chen, Xinli, Ning, Tingting, Chen, Hongyi, Guo, Qin, Zhang, Yiwen, Liu, Peixin, Zhang, Yujie, Li, Chao, Chu, Yongchao, Sun, Tao, Jiang, Chen·2021·Biomaterials
DOI 10.1016/j.biomaterials.2020.120546
Open this paper in CoChat — free account

Abstract

Immunotherapy has gained increasing focus in treating pancreatic ductal adenocarcinoma (PDAC), since conventional therapies like chemotherapy could not provide satisfactory improvement in overall survival outcome of PDAC patients. However, it is still not the game changing solution due to the unique tumor microenvironment and low cancer immunogenicity of PDAC. Thus, inducing more intratumoral effector immune cells as well as reversing immunosuppression is the core of PDAC treatment. Herein, we demonstrate an exosome-based dual delivery biosystem for enhancing PDAC immunotherapy as well as reversing tumor immunosuppression of M2-like tumor associated macrophages (M2-TAMs) upon disruption of galectin-9/dectin 1 axis. The deliver system is constructed from bone marrow mesenchymal stem cell (BM-MSC) exosomes, electroporation-loaded galectin-9 siRNA, and surficially modified with oxaliplatin (OXA) prodrug as an immunogenic cell death (ICD)-trigger. The use of biomaterials, BM-MSC exosomes, can significantly improve tumor targeting efficacy, thus increasing drug accumulation in the tumor site. The combined therapy (iEXO-OXA) elicits anti-tumor immunity through tumor-suppressive macrophage polarization, cytotoxic T lymphocytes recruitment and Tregs downregulation, and achieves significant therapeutic efficacy in cancer treatment.

Overview

Integrity signals

Registry

Crossref · 10.1016/j.biomaterials.2020.120546

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 7 references

Research works printed but not linked: 37

  1. Topalian, 2015, Immune checkpoint blockade: a common denominator approach to cancer therapy, Canc. Cell, 27, 450, 10.1016/j.ccell.2015.03.001 · DOI · Paper page
  2. Clark, 2007, Dynamics of the immune reaction to pancreatic cancer from inception to invasion, Canc. Res., 67, 9518, 10.1158/0008-5472.CAN-07-0175 · DOI · Paper page
  3. Fan, 2020, Current advances and outlooks in immunotherapy for pancreatic ductal adenocarcinoma, Mol. Canc., 19, 32, 10.1186/s12943-020-01151-3 · DOI
  4. Morrison, 2018, Immunotherapy and prevention of pancreatic cancer, Trends Cancer, 4, 418, 10.1016/j.trecan.2018.04.001 · DOI
  5. Daley, 2017, Dectin 1 activation on macrophages by galectin 9 promotes pancreatic carcinoma and peritumoral immune tolerance, Nat. Med., 23, 556, 10.1038/nm.4314 · DOI
  6. Seifert, 2020, Detection of pancreatic ductal adenocarcinoma with galectin-9 serum levels, Oncogene, 39, 3102, 10.1038/s41388-020-1186-7 · DOI
  7. Cowan, 2014, Genetic progression of pancreatic cancer, Canc. J., 20, 80
  8. Rucki, 2014, Pancreatic cancer stroma: understanding biology leads to new therapeutic strategies, World J. Gastroenterol., 20, 2237, 10.3748/wjg.v20.i9.2237 · DOI
  9. Fenton, 2018, Advances in biomaterials for drug delivery, Adv. Mater., 10.1002/adma.201705328 · DOI
  10. Stewart, 2017, Combinatorial drug delivery approaches for immunomodulation, Adv. Drug Deliv. Rev., 114, 161, 10.1016/j.addr.2017.05.013 · DOI
  11. Kim, 2016, Development of exosome-encapsulated paclitaxel to overcome MDR in cancer cells, Nanomedicine, 12, 655, 10.1016/j.nano.2015.10.012 · DOI · Paper page
  12. Vader, 2016, Extracellular vesicles for drug delivery, Adv. Drug Deliv. Rev., 106, 148, 10.1016/j.addr.2016.02.006 · DOI · Paper page
  13. Tran, 2015, Exosomes as nanocarriers for immunotherapy of cancer and inflammatory diseases, Clin. Immunol., 160, 46, 10.1016/j.clim.2015.03.021 · DOI
  14. Zhou, 2019, Bone marrow mesenchymal stem cells-derived exosomes for penetrating and targeted chemotherapy of pancreatic cancer, Acta Pharm. Sin. B, 10, 1563, 10.1016/j.apsb.2019.11.013 · DOI
  15. Vonderheide, 2013, Inflammatory networks and immune surveillance of pancreatic carcinoma, Curr. Opin. Immunol., 25, 200, 10.1016/j.coi.2013.01.006 · DOI
  16. Lu, 2017, Nano-enabled pancreas cancer immunotherapy using immunogenic cell death and reversing immunosuppression, Nat. Commun., 8, 1811, 10.1038/s41467-017-01651-9 · DOI
  17. Obeid, 2007, Calreticulin exposure dictates the immunogenicity of cancer cell death, Nat. Med., 13, 54, 10.1038/nm1523 · DOI · Paper page
  18. Michaud, 2011, Autophagy-dependent anticancer immune responses induced by chemotherapeutic agents in mice, Science, 334, 1573, 10.1126/science.1208347 · DOI · Paper page
  19. Liu, 2018, Platinum-based nanovectors engineered with immuno-modulating adjuvant for inhibiting tumor growth and promoting immunity, Theranostics, 8, 2974, 10.7150/thno.24110 · DOI
  20. Feng, 2018, Binary cooperative prodrug nanoparticles improve immunotherapy by synergistically modulating immune tumor microenvironment, Adv. Mater., 30, 10.1002/adma.201803001 · DOI
  21. Huang, 2019, Maleimide-thiol adducts stabilized through stretching, Nat. Chem., 11, 310, 10.1038/s41557-018-0209-2 · DOI
  22. Baron-Bodo, 2005, Anti-tumor properties of human-activated macrophages produced in large scale for clinical application, Immunobiology, 210, 267, 10.1016/j.imbio.2005.05.021 · DOI
  23. Alvarez-Erviti, 2011, Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes, Nat. Biotechnol., 29, 341, 10.1038/nbt.1807 · DOI · Paper page
  24. El-Andaloussi, 2012, Exosome-mediated delivery of siRNA in vitro and in vivo, Nat. Protoc., 7, 2112, 10.1038/nprot.2012.131 · DOI
  25. Mulcahy, 2014, Routes and mechanisms of extracellular vesicle uptake, J. Extracell. Vesicles, 3, 10.3402/jev.v3.24641 · DOI · Paper page
  26. Costa Verdera, 2017, Cellular uptake of extracellular vesicles is mediated by clathrin-independent endocytosis and macropinocytosis, J. Contr. Release, 266, 100, 10.1016/j.jconrel.2017.09.019 · DOI
  27. Horibe, 2018, Mechanism of recipient cell-dependent differences in exosome uptake, BMC Canc., 18, 47, 10.1186/s12885-017-3958-1 · DOI
  28. Kabashima-Niibe, 2013, Mesenchymal stem cells regulate epithelial-mesenchymal transition and tumor progression of pancreatic cancer cells, Canc. Sci., 104, 157, 10.1111/cas.12059 · DOI
  29. Wen, 2016, Mesenchymal stromal cell-derived extracellular vesicles rescue radiation damage to murine marrow hematopoietic cells, Leukemia, 30, 2221, 10.1038/leu.2016.107 · DOI
  30. Yeo, 2013, Mesenchymal stem cell: an efficient mass producer of exosomes for drug delivery, Adv. Drug Deliv. Rev., 65, 336, 10.1016/j.addr.2012.07.001 · DOI · Paper page
  31. Kroemer, 2013, Immunogenic cell death in cancer therapy, Annu. Rev. Immunol., 31, 51, 10.1146/annurev-immunol-032712-100008 · DOI · Paper page
  32. Sideras, 2017, PD-L1, Galectin-9 and CD8+ tumor-infiltrating lymphocytes are associated with survival in hepatocellular carcinoma, OncoImmunology, 6, 10.1080/2162402X.2016.1273309 · DOI
  33. Jiang, 2013, Decreased galectin-9 and increased Tim-3 expression are related to poor prognosis in gastric cancer, PloS One, 8, 10.1371/journal.pone.0081799 · DOI
  34. Wang, 2016, Reduced expression of galectin-9 contributes to a poor outcome in colon cancer by inhibiting NK cell chemotaxis partially through the rho/ROCK1 signaling pathway, PloS One, 11, 10.1371/journal.pone.0152599 · DOI
  35. Ohue, 2016, Survival of lung adenocarcinoma patients predicted from expression of PD-L1, galectin-9, and XAGE1 (GAGED2a) on tumor cells and tumor-infiltrating T cells, cancer immunol, Res., 4, 1049
  36. Irie, 2005, Galectin-9 as a prognostic factor with antimetastatic potential in breast cancer, Clin. Canc. Res., 11, 2962, 10.1158/1078-0432.CCR-04-0861 · DOI
  37. Joffre, 2012, Cross-presentation by dendritic cells, Nat. Rev. Immunol., 12, 557, 10.1038/nri3254 · DOI

Cited by

Sorted by citations

Metadata

Authors
Zhou, W., Zhou, Y., Chen, X., Ning, T., Chen, H., Guo, Q., Zhang, Y., Liu, P., Zhang, Y., Li, C., Chu, Y., Sun, T., & Jiang, C.
Venue
Biomaterials
Publisher
Elsevier BV
Published
2021-01
Volume
268
Pages
120546
ISSN
0142-9612
DOI
10.1016/j.biomaterials.2020.120546
Cited by
425
References
7
Language
en
Licence
Funders
  • Program of Shanghai Academic Research Leader
  • Science and Technology Commission of Shanghai Municipality
  • National Natural Science Foundation of China

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review